Reduced plasma hexosylceramides in frontotemporal dementia are a biomarker of white matter integrity

Documenti analoghi

• Longitudinal changes in functional capacity in frontotemporal dementia and Alzheimer's disease
  di: David Foxe, et al.
  Pubblicazione: (2024)
• Examining the propensity and nature of criminal risk behaviours in frontotemporal dementia syndromes and Alzheimer's disease
  di: Fiona Kumfor, et al.
  Pubblicazione: (2024)
• A Bayesian analysis of diagnostic timelines across Alzheimer's disease, frontotemporal dementia, and other neurodegenerative conditions
  di: Ananthan Ambikairajah, et al.
  Pubblicazione: (2025)
• Ethics of disclosure of onset‐predictive biomarker test results for genetic frontotemporal dementia in the research context
  di: Charlotte H. Graafland, et al.
  Pubblicazione: (2025)
• Modeling contributions of cognition and apathy to functional impairment in younger‐onset dementia
  di: Samuel L. Warren, et al.
  Pubblicazione: (2026)